Chordia Therapeutics (TSE:190A) Short-Term Debt: 円0.00 Mil (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:190A Chordia Therapeutics Inc TSE:190A
13 GF Score
Price 円82.00
! 1 Warning Sign
View Full Analysis

What is Chordia Therapeutics Short-Term Debt?

Chordia Therapeutics TSE:190A 13 Short-Term Debt is 円0.00 Mil as of Feb. 2026. GuruFocus rates TSE:190A with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Chordia Therapeutics's Short-Term Debt for the quarter that ended in Feb. 2026 was 円0.00 Mil.

Chordia Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Chordia Therapeutics Short-Term Debt Related Terms

Chordia Therapeutics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Chordia Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordia Therapeutics Short-Term Debt Chart

Chordia Therapeutics Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
Short-Term Debt
0.00 0.00 0.00 0.00 0.00

Chordia Therapeutics Quarterly Data
Aug21 Aug22 May23 Aug23 May24 Aug24 Feb25 May25 Aug25 Nov25 Feb26 May26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:190A
13GF Score
Chordia Therapeutics Inc TSE:190A
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of 円0.00 Mil mean?
Chordia Therapeutics (TSE:190A) has a Short-Term Debt of 円0.00 Mil as of Feb. 2026.
Is Chordia Therapeutics' Short-Term Debt too high?
Chordia Therapeutics' current Short-Term Debt is 円0.00 Mil. Overall, Chordia Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Chordia Therapeutics' Short-Term Debt compare to VRTX and REGN?
Chordia Therapeutics' Short-Term Debt of 円0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Chordia Therapeutics's current Short-Term Debt is 円0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordia Therapeutics stock overvalued right now?
Chordia Therapeutics (TSE:190A) has a current Short-Term Debt of 円0.00 Mil. The current Short-Term Debt is 円0.00 Mil. Chordia Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Chordia Therapeutics (TSE:190A), the current Short-Term Debt is 円0.00 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chordia Therapeutics Business Description

Address 2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.
13GF Score

Get the complete analysis for TSE:190A

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円82.00
Price